Lv12
100 积分 2025-03-04 加入
Unlocking the mechanisms underlying the activity of pembrolizumab plus enfortumab vedotin in patients with urothelial carcinoma
52分钟前
待确认
Antibody-drug conjugates in urothelial carcinoma: current status and future
1小时前
已完结
Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer
1小时前
已完结
Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer
1小时前
已完结
经膀胱前入路和经膀胱后入路机器人辅助前列腺癌根治术早期效果比较
1个月前
已完结
Sarcomatoid urothelial carcinoma: advances and challenges
1个月前
已关闭
高危非肌层浸润性膀胱癌的保膀胱策略研究进展
2个月前
已完结
Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer
2个月前
已完结
Global age-sex-specific all-cause mortality and life expectancy estimates for 204 countries and territories and 660 subnational locations, 1950-2023: a demographic analysis for the Global Burden of Disease Study 2023
3个月前
已完结
Postoperative functional and cancer control evaluation of conventional and Retzius-sparing robot-assisted radical prostatectomy: Comparison of selected cases by propensity score matching
3个月前
已完结
皖公网安备34019202002308
